Phenotypes associated with this allele

• Allele Symbol: Mir139^em1Jwli
• Allele Name: endonuclease-mediated mutation 1, Jianwen Liu
• Allele ID: MGI:6370186
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Mir139^em1Jwli/Mir139^em1Jwli	C57BL/6J-Mir139^em1Jwli	MGI:6370193

Genotype
MGI:6370193

hm1

• Allelic Composition: Mir139^em1Jwli/Mir139^em1Jwli
• Genetic Background: C57BL/6J-Mir139^em1Jwli

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

increased susceptibility to colitis induced morbidity/mortality ( J:248779 , J:280467 )

• mice with DSS-induced colitis show more than 80% mortality rate compared to 30% of wild-type mice (J:248779)

• DSS-treated mice exhibit increased weight loss, colon shortening and mortality with more severe diarrhea and hematochezia compared with wild-type mice (J:280467)

• AOM/DSS-treated mice exhibit increased weight loss and higher tumor burdens and tumor size with more severe diarrhea and hematochezia compared with wild-type mice (J:280467)

increased susceptibility to induced morbidity/mortality ( J:248779 )

• DSS and AOM treated mice show earlier and higher mortality than wild-type mice

increased susceptibility to xenobiotic induced morbidity/mortality ( J:280467 )

• after DSS treatment

digestive/alimentary system

decreased enterocyte apoptosis ( J:280467 )

• decreased in AOM/DSS-treated mice

abnormal enterocyte proliferation ( J:280467 )

• increased in AOM/DSS-treated mice

diarrhea ( J:248779 , J:280467 )

• in DSS-treated mice (J:248779)

• in DSS-treated mice (J:280467)

decreased colon length ( J:248779 )

• DSS and AOM treated mice exhibit reduced colon length

increased susceptibility to induced colitis ( J:248779 )

• mice exhibit increased susceptibility to DSS-induced colitis, showing sustained weight loss, rectal bleeding and diarrhea after removal of DSS compared to wild-type mice which start recovering

• DSS-induced mice show increased damage and delayed recovery of the epithelial layer, characterized by more infiltrating inflammatory cells, ulceration, and hyperplasia

• DSS-induced mice show increased inflammatory cytokines and chemokines which remain elevated during the recovery phase

increased susceptibility to colitis induced morbidity/mortality ( J:248779 , J:280467 )

• mice with DSS-induced colitis show more than 80% mortality rate compared to 30% of wild-type mice (J:248779)

• DSS-treated mice exhibit increased weight loss, colon shortening and mortality with more severe diarrhea and hematochezia compared with wild-type mice (J:280467)

• AOM/DSS-treated mice exhibit increased weight loss and higher tumor burdens and tumor size with more severe diarrhea and hematochezia compared with wild-type mice (J:280467)

neoplasm

increased incidence of tumors by chemical induction ( J:248779 , J:280467 )

• mice treated with both DSS and AOM show increased colitis-associated colorectal tumorigenesis, having a higher tumor burden in the colon and increased tumor size (J:248779)

• DSS and AOM treated mice develop aberrant crypt focus which progresses into tubular adenoma and adenocarcinoma (J:248779)

• tumors from DSS and AOM treated mice exhibit a higher proliferation rate and undergo less apoptosis than wild-type tumor cells (J:248779)

• higher tumor burdens, increased tumor size and high-grade dysplasia in AOM/DSS-treated mice (J:280467)

growth/size/body

increased susceptibility to weight loss ( J:248779 , J:280467 )

• in DSS-treated mice (J:248779)

• in DSS-treated mice (J:280467)

cellular

decreased enterocyte apoptosis ( J:280467 )

• decreased in AOM/DSS-treated mice

abnormal enterocyte proliferation ( J:280467 )

• increased in AOM/DSS-treated mice

homeostasis/metabolism

abnormal cytokine level ( J:248779 )

• DSS-induced mice show increased inflammatory cytokines and chemokines which remain elevated during the recovery phase

increased susceptibility to xenobiotic induced morbidity/mortality ( J:280467 )

• after DSS treatment

increased incidence of tumors by chemical induction ( J:248779 , J:280467 )

• mice treated with both DSS and AOM show increased colitis-associated colorectal tumorigenesis, having a higher tumor burden in the colon and increased tumor size (J:248779)

• DSS and AOM treated mice develop aberrant crypt focus which progresses into tubular adenoma and adenocarcinoma (J:248779)

• tumors from DSS and AOM treated mice exhibit a higher proliferation rate and undergo less apoptosis than wild-type tumor cells (J:248779)

• higher tumor burdens, increased tumor size and high-grade dysplasia in AOM/DSS-treated mice (J:280467)

immune system

increased susceptibility to induced colitis ( J:248779 )

• mice exhibit increased susceptibility to DSS-induced colitis, showing sustained weight loss, rectal bleeding and diarrhea after removal of DSS compared to wild-type mice which start recovering

• DSS-induced mice show increased damage and delayed recovery of the epithelial layer, characterized by more infiltrating inflammatory cells, ulceration, and hyperplasia

• DSS-induced mice show increased inflammatory cytokines and chemokines which remain elevated during the recovery phase

increased susceptibility to colitis induced morbidity/mortality ( J:248779 , J:280467 )

• mice with DSS-induced colitis show more than 80% mortality rate compared to 30% of wild-type mice (J:248779)

• DSS-treated mice exhibit increased weight loss, colon shortening and mortality with more severe diarrhea and hematochezia compared with wild-type mice (J:280467)

• AOM/DSS-treated mice exhibit increased weight loss and higher tumor burdens and tumor size with more severe diarrhea and hematochezia compared with wild-type mice (J:280467)

abnormal cytokine level ( J:248779 )

• DSS-induced mice show increased inflammatory cytokines and chemokines which remain elevated during the recovery phase